Introduction

Wheezing during early life represents a common disorder characterized by airways obstruction (1).

Recurrent wheezing have a significant morbidity and it’s estimated that about one third of school-age children manifest the symptom during the first 5 years of life (2).

In young children, wheezing, either transient or persistent, can be severe and cause a poor quality of life with frequent use of health care system and economic costs (1,2).

Wheezing is a common problem worldwide and the most frequent causes of wheezing in preschool children are bronchiolitis and asthma (1,3).

Parents of infants with recurrent wheezing often ask the pediatrician: “Will my children develop asthma?” This is a crucial question that involved also clinician in the diagnostic and therapeutic at tempts.

Proper identification of children at risk of developing asthma at school age may predict long-term outcomes and improve treatment and preventive approach, but the possibility to identify these children at preschool age remains limited.

Wheezing is a multi-factorial symptom, usually related to bronchiolitis or asthma, but other less common conditions may be consider in case of atypical presentation (1). Although most of the patients (60%) are expected to improve and to be symptom-free at the age of 6 years and the majority of them remain asymptomatic at the age of 11 and 16 years (4).

To better define the patients with wheezing, a tempts of classification, identification of asthma risk factors, genetic and environmental factors has been proposed to improve the characterization of children with recurrent wheezing.

Differential diagnosis

The differential diagnosis of chronic or recurrent wheezing is broad and includes structural or non-structural causes...
Structural defects include anatomic abnormalities such as tracheobronchial tree malacia and vascular ring or slings that manifest themselves early in life, typically in the first few months and are not responding to the therapy.

Non-structural causes are represented by various conditions that are related with recurrent wheezing. The most common ones are aspiration syndrome, foreign body inhalation, gastroesophageal reflux, fistulas and swallowing disorders related to neurologic or muscular dysfunction (5).

Recurrent infections of the lower respiratory tract can present as recurrent wheezing and host defense abnormalities may be considered.

Cystic fibrosis, bronchopulmonary dysplasia, obliterans bronchiolitis, interstitial lung disease and paradoxical vocal cord dysfunction are other causes to recognize.

Wheezing phenotypes

For many years authors focused their studies to identify early children with recurrent wheezing at risk to develop asthma at school age. They have proposed several phenotypes for a more precise characterization and a personalized plan of treatment. In 1995, Martinez et al., for the first time, introduced a classification focusing on three phenotypes: “transient wheezing”, “persistent wheezing” and “late onset wheezing” focusing on temporal appearance and persistence of symptoms (6). In 2008, an ERS task force reassessed the topic focusing on frequency and duration of associated symptoms and triggers (7). In particular wheezing in children were classified as “episodic viral wheezing” (EVW) or “multiple trigger wheezing” (MTW).

Recently, some studies revised the previous classifications of wheezing since they failed to be useful in clinical practice to manage children who were classified on symptom frequency and severity (8).

The main criticism concerns the inability to define stable phenotypes with the risk of overestimating or underestimating the characteristics of symptoms in these children (9).

In particular some authors of the 2008 ERS task force revised the contents taking into account the scientific evidence and clinical practice considerations (9).

The new document underlines how the previous classification, including EVW and MTW, was not useful and applicable in clinical practice because symptoms in children can be variable during the time and the two phenotypes can sometimes overlap (9).

Furthermore GINA guidelines revised in 2014 highlight the concept that asthma is already manifest in children under 5 years (10).

In this document authors emphasize the difficulty to diagnosis asthma at this age because of the frequency of episodes of upper respiratory infection and the lack of diagnostic instruments as spirometry to define bronchial-reversibility.

For this purpose GINA guidelines proposed frequency, gravity and duration of symptoms, inter critical manifestations, family history of atopy as tools to guide clinicians in asthma diagnosis and therapy (10).

It is suggested that a child with two or three episodes of wheezing in a year, lasting less 10 days, without symptoms between episodes has probably a viral bronchospasm with low probability to develop asthma (10). On the other hand a child with recurrent and longer episodes, familiar history of atopy associated with exercise induced wheezing has a higher probability to have asthma.

In the GINA document frequency, gravity, duration and time course of symptoms are recognized as the key features that the clinician must follow in diagnostic and therapeutic decision.

### Table 1 Differential diagnosis of recurrent wheezing

<table>
<thead>
<tr>
<th>Recurrent wheezing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural abnormalities</td>
</tr>
<tr>
<td>Tracheo-bronchomalacia</td>
</tr>
<tr>
<td>Vascular compression/rings</td>
</tr>
<tr>
<td>Tracheal stenosis/web</td>
</tr>
<tr>
<td>Cystic lesions/masses</td>
</tr>
<tr>
<td>Tumors/lymphadenopathy</td>
</tr>
<tr>
<td>Cardiomegaly</td>
</tr>
<tr>
<td>Functional abnormalities</td>
</tr>
<tr>
<td>Asthma</td>
</tr>
<tr>
<td>Gastroesophageal reflux</td>
</tr>
<tr>
<td>Recurrent aspiration</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>Immunodeficiency</td>
</tr>
<tr>
<td>Foreign body</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia</td>
</tr>
<tr>
<td>Bronchiolitis obliterans</td>
</tr>
<tr>
<td>Vocal cord dysfunction</td>
</tr>
<tr>
<td>Interstitial lung disease</td>
</tr>
</tbody>
</table>

(Shown in Table 1).

For the first time, introduced a classification focusing on three phenotypes: “transient wheezing”, “persistent wheezing” and “late onset wheezing” focusing on temporal appearance and persistence of symptoms (6). In 2008, an ERS task force reassessed the topic focusing on frequency and duration of associated symptoms and triggers (7). In particular wheezing in children were classified as “episodic viral wheezing” (EVW) or “multiple trigger wheezing” (MTW).

Recently, some studies revised the previous classifications of wheezing since they failed to be useful in clinical practice to manage children who were classified on symptom frequency and severity (8).

The main criticism concerns the inability to define stable phenotypes with the risk of overestimating or underestimating the characteristics of symptoms in these children (9).

In particular some authors of the 2008 ERS task force revised the contents taking into account the scientific evidence and clinical practice considerations (9).

The new document underlines how the previous classification, including EVW and MTW, was not useful and applicable in clinical practice because symptoms in children can be variable during the time and the two phenotypes can sometimes overlap (9).

Furthermore GINA guidelines revised in 2014 highlight the concept that asthma is already manifest in children under 5 years (10).

In this document authors emphasize the difficulty to diagnosis asthma at this age because of the frequency of episodes of upper respiratory infection and the lack of diagnostic instruments as spirometry to define bronchial-reversibility.

For this purpose GINA guidelines proposed frequency, gravity and duration of symptoms, inter critical manifestations, family history of atopy as tools to guide clinicians in asthma diagnosis and therapy (10).

It is suggested that a child with two or three episodes of wheezing in a year, lasting less 10 days, without symptoms between episodes has probably a viral bronchospasm with low probability to develop asthma (10). On the other hand a child with recurrent and longer episodes, familiar history of atopy associated with exercise induced wheezing has a higher probability to have asthma.

In the GINA document frequency, gravity, duration and time course of symptoms are recognized as the key features that the clinician must follow in diagnostic and therapeutic decision.
Asthma risk factors

A number of studies demonstrated that asthma is a multifactorial disease resulting from the interaction between genetic and environmental factors (Figure 1) (11).

Genetic studies on asthma revealed a large number of candidate genes associated with immune system that are potentially involved in pathogenesis of the disease (12).

Yang et al showed that cord blood IgE level, male sex, second hand cigarette smoke and parental history of atopy are predictive risk factors for recurrent wheezing (13). In particular they found a correlation with Clara cell protein CC10 G+38A polymorphism and lower CC10 levels in children with recurrent wheezing (13).

Other genetic markers were investigated, such as IL33-IL1RL1 pathway that has been associated with intermediate, late onset and persistent wheeze (14).

Other studies were performed about genetic involvement in asthma as a polymorphism in TNF-α as a potential genetic factor contributing in the development of wheezing and asthma (15).

Although further studies are still needed these findings may be useful for the early identification of children at the highest risk of developing recurrent episodes and the possibility to develop a specific pharmacotherapy.

Some studies have evaluated the relationship between atopy and asthma. In Tucson Children’s Respiratory Study Cohort (TCRS) predisposition to allergy appeared to be a primary risk factor in children with wheezing (6). Patients with late onset and recurrent wheezing had a higher sensitization to allergen at 6 ages those children without wheezing.

Children with IgE associated atopic persistent phenotype have the symptom that persists into adolescence (6). On the contrary children with non-atopic persistent wheezing generally have the first episode during first years of life and the wheezing episodes became less frequent in adolescence (16).

Environmental factors are also involved in asthma develop and exacerbations.

The hygiene hypothesis proposes that fewer infections in early life and lower exposure to microbes may shift the immune system from Th1 to Th2-biased allergic response in early life (17).

Changes in the intestinal microbiome have been demonstrated to be also involved in the increase of asthma prevalence and other allergic conditions (18).

Exposure to tobacco smoke, crowding, pets, dust mite are all considered important indoor allergens and irritants (18).

Air pollution, also, causes asthma exacerbations and increases hospital admission for respiratory symptoms (19).

Tobacco smoke is an important indoor air pollutant that is involved in asthma development during childhood (20).

Exposure to tobacco by products are transferred from placenta to the foetus (20). In an animal model epigenetic changes due to tobacco exposure during pregnancy increased the risk of wheezing therefore suggesting asthma risk after birth (21).

Recently has been proposed a role of vitamin D and antioxidant on development of asthma. The effect of vitamin D and trace elements has been discussed in recurrent wheezing. In particular there is a positive correlation between a decreased intake of antioxidants and increased incidence of the disease (22).

Vitamin D and trace elements can act as anti-inflammatory and anti-oxidant agents on host immune system. A reduction of these elements in diet intake increases oxidant damage and derangement of the immune system (23).

A diet poor in antioxidants makes the host more vulnerable to reactive oxygen species. Vitamin D and trace elements have an immune modulator effect and can be effective in respiratory tract infections.

Predictive index in children with wheezing

In the last years there has been a significant increase of asthma diagnosis in children and a decrease in the age of asthma diagnosis (24).

Various asthma predictive indexes (APIs) have been
developed in the last years to identify children at risk of asthma in preschool age. Epidemiologic studies have employed various risk factors associated with the development of asthma such as parental history of atopy, wheezing history, IgE levels and cytokines profiles.

API is a validated clinical model for childhood asthma defined on a cohort of children who wheeze at least one time during the first 3 years of life (25-27).

The primary criteria to identify the score are ≥4 episodes of wheezing in 1 year and the secondary are clinician diagnose of parental eczema or asthma, allergic sensitization to aeroallergen, wheezing unrelated to cold, eosinophilia ≥4 percent (26). A positive index was defined as at least major criterion plus at least one major or two minor criteria (26).

API sensitivity is low, suggesting that the test is poor for predicting later asthma development. Nevertheless API has a high negative predictive value, meaning that it can identify children who have a low probability to develop asthma with a negative test.

A modified version (mAPI) was tested in a cohort of high risk children with a family history of allergy and/or asthma (28). A positive mAPI increased the probability to identify patient at risk to develop future asthma.

Another simple tool was developed by Pescatore et al. (29). The questionnaire is a simple and robust tool to assess the prevalence of asthma 5 years later in preschool children with wheeze or cough (29).

The index considers only non-invasive predictors that are easy to assess in primary care such as demographic and perinatal data, eczema, upper and lower respiratory tract symptoms and family history of atopy. The score can stratify patients with high, medium or low risk to develop asthma. This is a simple, low-cost and noninvasive method to predict the risk of later asthma in symptomatic preschool children.

**Therapeutic strategy**

The approach to the treatment of preschool wheezing has been widely discussed and recently revised (9,10). A significant reconsideration of the role of ICS in this population has been based on a review and meta-analysis considering 29 studies in pre-schooler wheezers (30).

The meta-analysis has demonstrated that ICS are effective in reducing the frequency of wheezing episodes during preschool age, irrespective of phenotype or atopy status (30).

Furthermore, authors underline the importance of the adherence to ICS therapy in children aged two-six years in the control of asthma symptoms.

The re-emerging potential role of ICS in the treatment of wheezing in preschool age has also opened the question whether the preferred treatment in this categories should be low dose ICS daily or higher dose ICS intermittent.

A couple of studies showed no difference in number and severity of exacerbations between the two strategies with a lower ICS use with the intermittent design.

The intermittent use of high dose of ICS represents one a relevant new option in the management of wheezing in pre-schooler proposed by either 2014 ERJ review and GINA document (9,10).

This therapeutic strategy was proposed by a number of studies show in the last few years.

Bacharier et al. evaluated the efficacy of high intermittent dose of budesonide (1,000 mcg twice daily) for one week when the patient has the first symptoms of respiratory infection in preschool children with recurrent wheezing. They demonstrated a significative reduction in severity of relapses in particular in children with a positive API.

The BEST study showed that a regular low dose of BPD was the most effective treatment for preschool children with recurrent wheezing. A valid alternative was intermittent salbutamol and BPD (80 mcg daily) during exacerbations with a significant reduction in ICS total dose (31).

Ducharme et al. showed also a reduction in the use of oral corticosteroid in preschool children with the intermitted high dose use of fluticasone (1,500 mcg/day), but it underlines the warning on a negative effect on growth in a half of patients at such high dosage (32). The dose utilised in the study in fact is far higher than usually use in clinical practice.

A study evaluated the effect of high dose of nebulized BPD in children with viral wheeze (33). The authors observed a reduction in the number of episodes and number of children with wheeze in the group with active drug compared with placebo.

These studies support the “non-genomic effect” of ICS in the treatment of episodic wheezing in preschool children. In fact while the anti-inflammatory effect of ICS is based on the cellular activation by genomic pathways the “non-genomic” effect based on vasoconstriction and reduction of airways blood flow, relevant during preschool wheezing due to viral infections (34).

The two most significant studies on intermittent ICS use were performed using pneumatic nebulizer (31,35).
This issue is very relevant in the real life setting. In fact, although guidelines consider metered dose inhalers (MDI) plus spacer as first choice, in the real life nebulizers are commonly used in both USA and Europe (10).

These results also support the recommendation from the group of ERS experts and the recent revision of GINA document. In particular, GINA initiative has a dedicate chapter on diagnosis and management of asthma in children under five. The approach proposed in GINA document is focused on frequency and severity of wheezing episodes in correlation with inter critical symptoms and family history of atopy in order to define the risk of children to develop asthma. A child with two or three episodes in 1 year, each lasting less than 10 days without inter critical symptoms has less probability to be asthmatic and to have benefit from a regular controller therapy. On the other hand, a child with frequent, long lasting symptoms, exercise induced wheezing and a family history of atopy is more probably an asthmatic subject for whom a low regular dose of ICS therapy may be consider the most appropriate treatment.

Furthermore, intermitted ICS was also proposed for children with intermittent viral induced wheeze without symptoms between episodes, if short acting β2 agonist (SABA) is not sufficient.

**Conclusions**

In the last years wheezing in preschool children has been widely reconsidered.

The classification of children with wheezing is now mainly based upon the severity and frequency of episodes rather on specific phenotypes, previously proposed.

The therapeutic approach is now based upon symptoms severity and frequency. A regular ICS treatment is consider more effective in asthmatic children and in those with recurrent wheezing and inter critical symptoms. Intermittent ICS is now considered as a valid option for preschool children with intermittent viral induced wheezing and no interval symptoms.

**Acknowledgements**

None.

**Footnote**

_Conflicts of Interest:_ G Piacentini has served in advisory boards for Aerocrine AB, Chiesi S.p.A., Sensor Medics Italia s.r.l., Stallergenes Italia s.r.l. and received lectures fees for Aerocrine AB, Chiesi S.p.A., Italchimici S.p.A., Meda Pharma S.p.A., ThermoFisher/Phadia s.r.l. The other authors have no conflicts of interest to declare.

**References**


